Genetron Holdings Ltd Stock Price, News & Analysis

Genetron Holdings Limited (NASDAQ: GTH) announced on August 22, 2022, that its Board received a non-binding proposal from co-founder and CEO Sizhen Wang to acquire all outstanding shares for US$0.272 each or US$1.36 per ADS. The transaction, which will be funded through a mix of debt and equity, is under review by a special committee formed by independent directors. The Board cautions that evaluations are ongoing, and no definitive agreement has been reached. Shareholders should reference the SEC’s upcoming filings for detailed information on the proposal.

Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, announced participation in the virtual Goldman Sachs Healthcare Corporate Day on June 24, 2022. Management, including CEO Sizhen Wang and CFO Evan Xu, will attend investor meetings. Genetron specializes in molecular profiling tests, early cancer screening, and companion diagnostics, leveraging advanced molecular biology and data science technologies. The company offers a comprehensive oncology portfolio addressing cancer management needs and collaborates with global biopharmaceutical firms. For more information, visit Genetron Health's website.

Genetron Holdings Limited (NASDAQ: GTH) announced its Maryland laboratory has received College of American Pathologists (CAP) Accreditation. This designation enhances Genetron's ability to meet regulatory standards and improve test accuracy, supporting its U.S. drug development services. The Maryland lab joins the company's main Beijing facility as CAP and CLIA accredited. This accreditation strengthens Genetron's partnerships in global oncology drug research and development, showcasing its capabilities in precision oncology and companion diagnostics.

Genetron Holdings Limited (NASDAQ: GTH) reported a 19.8% increase in total revenue for Q1 2022, reaching RMB 110.3 million (US $17.4 million). Growth was driven by LDT services, which rose 13.5% to RMB 81.5 million (US $12.9 million), and IVD products seeing an 18.1% increase to RMB 18.0 million (US $2.8 million). However, operating expenses surged 47.6% to RMB 241.4 million (US $38.1 million), leading to an operating loss of RMB 179.9 million (US $28.4 million). The company maintains its 2022 revenue guidance of RMB 585-638 million (10-20% growth).

Genetron Holdings Limited (Nasdaq: GTH) announced the presentation of 10 significant research results at the 2022 ASCO Annual Meeting. These studies, utilizing Genetron's One-Step™ Seq Method, focus on gene mutation characteristics and fusion mapping in various cancers, including lung and gastric cancers. Collaborating with over 10 leading hospitals in China, the results aim to guide clinical diagnosis and treatment, enhancing the potential for personalized therapies. Key areas explored include gene fusions, molecular characteristics guiding treatment, and predicting immunotherapy efficacy.

Genetron Holdings Limited (GTH) announced a significant milestone with the CE Mark approval of its FusionScan Plus Kit, a molecular profiling assay designed to detect multiple gene mutations and fusions simultaneously. This innovative product employs Genetron's One-Step™ Seq Method and covers 29 mutant genes and 40 fusion genes, improving detection accuracy and clinical application. The CE Mark enhances FusionScan Plus's potential for international trials, signaling Genetron's commitment to expanding its reach in precision oncology and addressing clinical needs with advanced testing solutions.

Genetron Holdings Limited (NASDAQ: GTH) announced it will release its unaudited financial results for Q1 ended March 31, 2022, on June 2, 2022, prior to U.S. market open. Management will host an investor conference call at 8:30 a.m. ET the same day. Genetron Health is recognized as a leading precision oncology platform in China, focusing on molecular profiling tests and early cancer screening products. The company continues to innovate in the field of cancer management by partnering with global biopharmaceutical companies.

Genetron Holdings Limited (Nasdaq: GTH) has received a CE Mark for its Seq-MRD® assay, enhancing its portfolio in precision oncology. This test, designed for detecting minimal residual disease in patients with B lymphocytic leukemia and multiple myeloma, employs advanced sequencing technology and aims at improving treatment follow-up. The assay showed high sensitivity and accuracy compared to traditional flow cytometry methods. Following a commercialization agreement with Jiangsu Fosun Pharma, Genetron plans to market this product in hematologic hospitals across China, reinforcing its commitment to precise cancer care.

Genetron Holdings Limited (Nasdaq: GTH) announced 17 research results at the AACR 2022, focusing on cancer genomics and molecular profiling. Collaborating with over 20 hospitals, Genetron presented findings on various cancers, including lung, gastric, and bladder cancers, using patented technologies like Onco PanScan™. Highlights include the potential for PARP inhibitors in sarcoma and urine genetic tests for muscle-invasive bladder cancer. The studies aim to enhance early diagnosis and treatment, showcasing Genetron's commitment to advancing precision oncology.